Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer

Fig. 7

Study Design and Ascore Prognostic Validity Evaluation in Gulou-Cohort1. A Retrospective study stratification flowchart showing Gulou-Cohort1 (134 patients) and Gulou-Cohort2 (40 patients) compositions. Circulating tumor cells were successfully isolated and quantified from 62 Gulou-Cohort1 patients' blood samples. B Kaplan–Meier curves comparing prognostic outcomes between the high and low Ascore groups in Gulou-Cohort1. C ROC analysis showing Ascore’s predictive value versus CTC counts and ECOG score in Gulou-Cohort1. (CTC: Circulating tumor cell; ECOG: Eastern Cooperative Oncology Group)

Back to article page

Molecular Cancer

ISSN: 1476-4598